Osiris Therapeutics Inc. | Income Statement
Fiscal year is January-December. All values USD Thousands.
2012
2013
2014
2017
Sales/Revenue
11,804.00
25,698.00
50,835.00
118,514.00
Cost of Goods Sold (COGS) incl. D&A
2,551.00
6,851.00
9,886.00
32,681.00
Gross Income
9,253.00
18,847.00
40,949.00
85,833.00
SG&A Expense
20,404.00
20,858.00
47,933.00
87,822.00
EBIT
11,151.00
-
6,984.00
1,989.00
Unusual Expense
-
-
401.00
-
Non Operating Income/Expense
49.00
414.00
1,370.00
645.00
Pretax Income
11,102.00
1,597.00
8,755.00
2,634.00
Income Tax
37.00
994.00
97.00
1,398.00
Consolidated Net Income
11,065.00
603.00
8,852.00
1,236.00
Net Income
11,065.00
603.00
8,852.00
1,236.00
Net Income After Extraordinaries
11,065.00
43,666.00
7,734.00
11,257.00
Net Income Available to Common
11,065.00
7,271.00
9,970.00
8,785.00
EPS (Basic)
0.34
1.27
0.29
0.25
Basic Shares Outstanding
32,859.00
33,307.00
34,263.00
34,524.00
EPS (Diluted)
0.34
1.27
0.29
0.25
Diluted Shares Outstanding
32,859.00
33,307.00
34,263.00
34,525.00
EBITDA
10,443.00
1,424.00
6,044.00
1,301.00
About Osiris Therapeutics
View Profile
